Goldman Sachs
VIRX

Goldman Sachs’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Goldman Sachs’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-372
Closed -$558K – 7351
2014
Q3 		$558K Buy
+372
New +$539K ﹤0.01% 5165

Other funds holding VIRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's VIRX Position: Q4 2024 in Review

Goldman Sachs sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2024, closing a stake of 27,090 shares — an estimated $6.27K sold.

Goldman Sachs first reported a position in VIRX in Q2 2013 and held it in 25 quarters. The position peaked at $5.59M in Q1 2021. 32 funds tracked by Wall St. Rank hold VIRX as of Q4 2024.

  • Goldman Sachs reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Goldman Sachs sold 27,090 Viracta Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $6.27K.
  • Goldman Sachs first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 25 quarters.
  • Goldman Sachs's Viracta Therapeutics, Inc. Common Stock position peaked at $5.59M in Q1 2021.
  • 32 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Goldman Sachs's 13F filing for Q4 2024, filed 11 Feb 2025.